

抗癌藥物治療指引

膽管癌

討論日期

團隊制訂：2019/12/31

核備日期：2020/3/31

《膽管癌抗癌藥物治療指引》

Intrahepatic/Extrahepatic Cholangiocarcinoma

Post resection

R0, R1 resection

Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 (750-1000)* PO BID	1-14	Q3W	8	1

*團隊共識

Gemcitabine-based chemotherapy followed by fluoropyrimidine-based chemoradiation

Gemcitabine+Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	4	5
Capecitabine	1500 (750-1000)*	1-14	Q3W	4	
Followed by					
Capecitabine	1330 (750-1000)*	1-14	Q3W	4	

Unresectable/Metastatic disease

Gemcitabine + Cisplatin

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	8	2
Cisplatin	25~40*	1, 8	Q3W	8	

*團隊共識

Gemcitabine + Oxaliplatin

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8, 15	Q4W		3
Oxaliplatin	100 (85-100)*	1, 15	Q4W		

*團隊共識

Oxaliplatin + Capecitabine

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q4W		3
Capecitabine	1000 (750~1000)* PO BID	1-14	Q4W		

*團隊共識

Cisplatin + 5 Fu

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q3W		4
5-FU	1000	1-5	Q3W		

Pembrolizumab (only for MSI-H/dMMR tumors)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W		6

Nivolumab

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W	8	7
Followed by					
Nivolumab	480 mg	1	Q4W	24	

參考文獻

1. Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer.
2. Valle JW, Wasan HS, Palmer DD, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Eng J Med* 2010;362:1273-1281.
3. Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. *Br J Cancer* 2006;95(7):848-52.
4. Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. *Br J Cancer* 2008;98(2):309-15.
5. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. *J Clin Oncol*. 2015;33(24):2617-22.
6. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol*. 2020;38(1):1-10.
7. Richard D. Kim, Dae Won Kim, et al. A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). *J Clin Oncol*. 2019;37:15_suppl, 4097-4097.